Compare PUBM & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PUBM | MLTX |
|---|---|---|
| Founded | 2006 | 2021 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 847.2M | 863.0M |
| IPO Year | 2020 | 2020 |
| Metric | PUBM | MLTX |
|---|---|---|
| Price | $16.03 | $11.91 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 15 |
| Target Price | $21.00 | ★ $28.54 |
| AVG Volume (30 Days) | 495.5K | ★ 1.9M |
| Earning Date | 11-09-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $282,926,000.00 | N/A |
| Revenue This Year | $9.05 | N/A |
| Revenue Next Year | $8.32 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.15 | $9.46 |
| 52 Week High | $19.30 | $23.29 |
| Indicator | PUBM | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 36.62 | 51.73 |
| Support Level | $16.02 | $11.88 |
| Resistance Level | $18.16 | $13.51 |
| Average True Range (ATR) | 0.79 | 0.77 |
| MACD | -0.19 | 0.33 |
| Stochastic Oscillator | 4.03 | 63.37 |
PubMatic Inc is is an independent, artificial intelligence-powered advertising technology company that delivers digital advertising performance. Its integrated technology platform connects buyers, publishers, data providers, and commerce media networks on a single, unified platform, to deliver advertising performance, control, transparency and efficiency. Its platform empowers the world's digital content creators (publishers) to maximize monetization of their advertising inventory and audiences and provides control and transparency to buyers, which includes advertisers, agencies, agency trading desks, and demand side platforms (DSPs) (referred as buyers). Geographically, the company generates the majority of its revenue from the United States, followed by EMEA, APAC, and Rest of the World.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.